Encysive Pharma Shares Plummet
Encysive Pharma (ENCY) shares plunged Monday after the company received an Approvable Letter requesting additional clinical trial work from the FDA for Thelin, which is under review for treatment of pulmonary arterial hypertension. Brean Murray, First Albany, and Needham each downgraded the shares.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.